歡迎光臨源葉生物,登錄 | 注冊 |
當(dāng)前位置: 首頁 > 小分子抑制劑 > GPCR/GProtein > Etrasimod

瀏覽歷史

S82326

Etrasimod

源葉(MedMol) 99%
  • 英文名:
  • Etrasimod
  • 別名:
  • (R)-2-(7-(4-環(huán)戊基-3-(三氟甲基)芐氧基)-1,2,3,4-四氫環(huán)戊并[b]吲哚-3-基)乙酸;APD334; (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; (R)-2-(7-((4-cyclopentyl-3-(
  • CAS號:
  • 1206123-37-6
  • 分子式:
  • C26H26F3NO3
  • 分子量:
  • 457.4847
  • 核磁/質(zhì)譜:
品牌貨號產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S82326-1mg 99% ¥160.00元 10 - - - EA 加入購物車
源葉(MedMol) S82326-5mg 99% ¥360.00元 6 - - - EA 加入購物車
源葉(MedMol) S82326-10mg 99% ¥570.00元 6 - - - EA 加入購物車
源葉(MedMol) S82326-25mg 99% ¥1150.00元 6 - - - EA 加入購物車
大包裝詢價(jià)

提交您的電話號碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells
  • 靶點(diǎn): IC50: 1.88 nM (S1P1);S1PReceptor;?LPLReceptor
  • 體外研究:
    APD334 is a structurally novel, selective, functional antagonist of S1P1. In CHO cells expressing HA tagged S1P1, APD334 is found to have an IC50?value of 1.88 nM. Moderate agonism at human S1P4?and S1P5?is observed but is reduced relative to S1P1, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P2?and S1P3. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P1?activity is maintained in mice (EC50=0.44 nM), rats (EC50=0.32 nM), dogs (EC50=0.34 nM) and monkeys (EC50=0.32 nM)
  • 體內(nèi)研究:
    APD334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high Cmax?across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t1/2?values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively
  • 參考文獻(xiàn):
    1. Buzard DJ, et al. Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.186 ml 10.929 ml 21.859 ml
    5 mM 0.437 ml 2.186 ml 4.372 ml
    10 mM 0.219 ml 1.093 ml 2.186 ml
    50 mM 0.044 ml 0.219 ml 0.437 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells
  • 靶點(diǎn): IC50: 1.88 nM (S1P1);S1PReceptor;?LPLReceptor
  • 體外研究:
    APD334 is a structurally novel, selective, functional antagonist of S1P1. In CHO cells expressing HA tagged S1P1, APD334 is found to have an IC50?value of 1.88 nM. Moderate agonism at human S1P4?and S1P5?is observed but is reduced relative to S1P1, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P2?and S1P3. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P1?activity is maintained in mice (EC50=0.44 nM), rats (EC50=0.32 nM), dogs (EC50=0.34 nM) and monkeys (EC50=0.32 nM)
  • 體內(nèi)研究:
    APD334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high Cmax?across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t1/2?values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively
  • 參考文獻(xiàn):
    1. Buzard DJ, et al. Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.186 ml 10.929 ml 21.859 ml
    5 mM 0.437 ml 2.186 ml 4.372 ml
    10 mM 0.219 ml 1.093 ml 2.186 ml
    50 mM 0.044 ml 0.219 ml 0.437 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩